Searched for
INTAS PHARMACEUTICALS
Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution ProcessThe Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP)...
- Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
- Intas Pharma launches its first biosimilar product Accofil in EuropeThe product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.
- Intas Pharmaceuticals sells ChrysCapital’s stake to TemasekIntas Pharmaceuticals Ltd has announced that Singapore investment company Temasek has acquired a 10.16% equity stake in the company.
- Delhi High Court comes to Intas rescue, stops Arinna Lifescience for trademark violationDelhi High Court gave relief to Ahmedabad-based drug maker, Intas Pharmaceuticals, by granting an ex-parte injunction against the sale of V...
- CCI clears Temasek's 10.16% stake buy in Intas PharmaceuticalsTemasek Holding's proposed 10.16% stake purchase in Indian firm Intas Pharmaceuticals has got the approval of the Competition Commission.
- ChrysCapital to sell 10% in drug maker Intas Pharmaceuticals to Temasek for over $160 millionTemasek has bought 12.5% stake in Intas Pharmaceuticals, one of India's top 10 drug makers by sale, for a little over Rs 1,100 crore, peopl...
- IPO: Sebi gives green signal to offerings of Advanced Enzyme Tech, Intas PharmaMarket regulator Sebi has given nod to the proposed initial public offerings of two companies-- Advanced Enzyme Technologies and Intas Phar...
- Intas settles patent litigation with Hoffmann-La Roche for capecitabine tabletAhmedabad-based drug maker, Intas Pharmaceuticals Ltd and its US-based wholly owned subsidiary Accord Healthcare Inc. has entered into a se...
- Claris Lifesciences gets USFDA drug approvalClaris Lifesciences Ltd, a parenteral drug company has received drug approval from US drug authorities for hypertension and angina treatmen...
- Intas ex-employee objects to amalgamation planAn affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, ...
- ChrysCap to buy Rs 300-cr stake in Intas PharmaceuticalsPrivate equity firm ChrysCapital is buying an additional stake in Intas Pharmaceuticals for Rs 300 crore after the Ahmedabad-based drug mak...
- ChrysCapital set to raise stake in Intas Pharmaceuticals ahead of deferred IPOAlthough the stake could not be be confirmed, the pre-IPO deal will increase ChrysCapital's holding in the company to over 15% from 11.3% c...
- ChrysCapital, Blackstone and Advent Capital in race to buy stake in Intas Pharma for Rs 250 crore3 PE firms are vying for a minority stake in generic drugmaker Intas Pharmaceuticals, two people familiar with the development told ET.
- Intas Pharma files documents with Sebi for IPODrug maker Intas Pharmaceuticals today said it has filed documents with market regulator Sebi for an initial public offer that includes sal...
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
- Mauritius-based FIIs to pick up 47% in Intas' biotech armA clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
Load More
